T46.0X2 Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm

Name of the Condition

• Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm

Summary

This code describes poisoning resulting from intentional self-harm involving cardiac-stimulant glycosides or drugs with similar actions. These substances, such as digoxin, are used to treat heart conditions like atrial fibrillation and heart failure. Intentional self-harm indicates deliberate exposure, which may present with varying severity depending on the dose and individual factors. Clinical management focuses on stabilizing the patient and addressing underlying mental health concerns.

Causes

Intentional self-harm poisoning occurs when an individual deliberately ingests or administers cardiac-stimulant glycosides or similar drugs to cause harm. This may involve taking excessive doses of prescribed medications or accessing these substances through other means. The intent to self-harm is a key factor in distinguishing this scenario from accidental or therapeutic-related exposures.

Risk Factors

• Access to cardiac-stimulant glycosides (e.g., prescribed medications or stored supplies).
• History of mental health conditions, such as depression or suicidal ideation.
• Prior episodes of self-harm or substance misuse.
• Social or environmental stressors contributing to intentional harm.

Symptoms

• Nausea, vomiting, or abdominal pain.
• Irregular heart rhythms (arrhythmias), including bradycardia or tachycardia.
• Dizziness, fainting, or syncope.
• Visual disturbances (e.g., blurred vision, yellow-green halos around lights).
• Weakness, fatigue, or confusion.
• Seizures or cardiac arrest in severe cases.

Diagnosis

Diagnosis requires a thorough patient history to confirm intentional self-harm and identify the specific substance involved. Clinical assessment includes evaluating symptoms, vital signs, and electrocardiogram (ECG) findings for arrhythmias. Laboratory tests, such as serum drug levels, may help quantify exposure. Mental health evaluation is essential to address underlying intent and plan follow-up care.

Treatment Options

Treatment focuses on stabilizing the patient, managing symptoms, and preventing further harm. Interventions may include activated charcoal to reduce absorption, medications to correct arrhythmias (e.g., digoxin-specific antibodies), and supportive care for cardiac or neurological symptoms. Psychiatric consultation is critical for assessing suicide risk and initiating appropriate mental health support.

Prognosis and Follow-Up

Prognosis depends on the dose ingested, time to treatment, and presence of complications. Early intervention improves outcomes, but severe poisoning can lead to long-term cardiac or neurological damage. Follow-up includes monitoring for recurrence, addressing mental health needs, and ensuring safe storage of medications to prevent future incidents.

Complications

• Persistent arrhythmias or heart failure.
• Neurological damage, such as seizures or coma.
• Kidney injury from toxin accumulation.
• Psychological effects, including depression or anxiety.
• Increased risk of future self-harm episodes.

Lifestyle & Prevention

• Secure storage of medications to limit access.
• Education on recognizing and reporting suicidal thoughts or behaviors.
• Regular mental health check-ins for at-risk individuals.
• Collaboration between healthcare providers and mental health professionals to address underlying issues.

When to Seek Professional Help

Seek immediate medical attention if intentional self-harm with cardiac-stimulant glycosides is suspected or confirmed. Signs of poisoning, such as severe symptoms or altered mental status, require urgent evaluation. Mental health support should be sought promptly to address suicidal ideation and prevent recurrence.

Tips for Medical Coders

This code is used for cases of intentional self-harm poisoning by cardiac-stimulant glycosides or similar drugs. Document the intent (intentional self-harm) clearly in the medical record, as this distinguishes it from accidental or therapeutic-related exposures. Include details about the substance involved, clinical presentation, and any mental health assessments to support coding accuracy.